Filing Flows › Joint (JYNT) › Guidance & outlook
Joint (JYNT) guidance and outlook
Joint (JYNT) lowered its guidance on Nov 5, 2026: EBITDA $12.5M–$13.5M for FY2026. Joint's 10-Q filed Nov 6, 2026 makes 19 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $508M–$512M | lowered |
| Revenue | FY2026 | −3.5% to −2.5% | new |
| EBITDA | FY2026 | $12.5M–$13.5M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- We will continue our franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry.
- After evaluating options for improvement, during 2023, our Board of Directors authorized management to initiate a plan to refranchise or sell the majority of our company-owned or managed clinics.
- During the third quarter of 2024, we expanded the refranchising plan to include the full portfolio of our company-owned or managed clinics, marketing the clinics in large clusters grouped primarily by geographic location.
- On December 5, 2025, we entered into an Asset Purchase Agreement with Addisco Value, LLC, a North Carolina limited liability company, Triangle Chiropractic Associates P.C., a North Carolina professional corporation, and Bluffton TJ, LLC, a South Carolina limited liability company, collectively as buyers, pursuant to which we will sell the assets of, and grant franchise rights
- On April 20, 2026, we entered into the Elite Chiro Group Purchase Agreement with Elite Chiro Group, pursuant to which we will sell to Elite Chiro Group the assets of, and grant franchise rights to, 45 company-owned or managed clinics located in Southern California for an aggregate purchase price of $2.3 million, subject to certain adjustments.
- On June 28, 2026, we entered into an Asset Purchase Agreement (the “Vigeo Purchase Agreement”) with Vigeo, LLC, a California limited liability company (“Vigeo”), as buyer, pursuant to which we will sell the assets of, and grant franchise rights to, four company-owned or managed clinics located in Northern California for an aggregate purchase price of $400 thousand.
- As of September 30, 2026, we have closed on the sale of the four company-owned or managed clinics included in the Vigeo Purchase Agreement and have recorded a $287 thousand note receivable that will be paid in full upon the maturity date of October 1, 2028.
- Based on the foregoing, we agreed to pay to the Texas Sellers an aggregate purchase price of $8.0 million in cash that was due upon execution of the Texas Purchase Agreement, and if certain gross sales metrics are met or exceeded under the Texas RDAs during the two annual periods beginning September 1, 2026, we will also pay to the Texas Sellers up to $2.0 million in additional consideration payments, split…
- Our goal will be to generate significant proceeds that will provide us with value creating capital allocation opportunities.
- We will continue to leverage the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country and will continue to evaluate opportunities to bring regional development territories under our direct structure as we advance our long-term growth strategy and expands access to chiropractic care in communities nationwide.
- We believe that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness.
- We anticipate that 2026 will continue to be a volatile macroeconomic environment.
Joint's latest quarter
Joint, Q3 2026: revenue $13.6M (+1% year over year), operating margin 9.8%, net loss $117K, operating cash flow −$128K. The chart follows the revenue to costs, profit and cash.
Questions
Did Joint raise or lower its guidance?
Joint (JYNT) lowered its guidance on Nov 5, 2026: EBITDA $12.5M–$13.5M for FY2026.
What does Joint expect?
We will continue our franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry. After evaluating options for improvement, during 2023, our Board of Directors authorized management to initiate a plan to refranchise or sell the majority of our company-owned or managed clinics. During the third quarter of 2024, we expanded the refranchising plan to include the full portfolio of our company-owned or ma
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.